Menu Search
Equities

Medicure Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NGQ1:STU

Medicure Inc

Actions
  • Price (EUR)0.67
  • Today's Change-0.02 / -2.90%
  • Shares traded0.00
  • 1 Year change+51.58%
  • Beta0.9298
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Medicure Inc. is a pharmaceutical company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. It operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. It operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. It develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.

  • Revenue in CAD (TTM)26.21m
  • Net income in CAD-3.43m
  • Incorporated2000
  • Employees23.00
  • Location
    Medicure Inc1250 Waverley StreetWINNIPEG R3T 6C6CanadaCAN
  • Phone+1 (204) 487-7412
  • Fax+1 (204) 487-7412
  • Websitehttps://www.medicure.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.